Kaken Pharmaceutical Co., Ltd.
KKPCF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.15 | 0.36 | -0.63 | -0.70 |
| FCF Yield | 16.86% | 0.30% | 4.83% | 5.48% |
| EV / EBITDA | 4.56 | 7.18 | 9.60 | 7.74 |
| Quality | ||||
| ROIC | 9.21% | 4.98% | 4.27% | 7.82% |
| Gross Margin | 62.24% | 53.49% | 54.20% | 54.68% |
| Cash Conversion Ratio | 1.53 | 0.32 | 1.36 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.81% | -1.78% | -0.89% | -5.20% |
| Free Cash Flow Growth | 6,092.20% | -94.18% | -30.08% | -16.66% |
| Safety | ||||
| Net Debt / EBITDA | -2.28 | -3.72 | -5.93 | -3.49 |
| Interest Coverage | 751.21 | 559.59 | 470.47 | 1,003.76 |
| Efficiency | ||||
| Inventory Turnover | 1.87 | 1.95 | 2.15 | 2.30 |
| Cash Conversion Cycle | 193.59 | 231.32 | 198.39 | 193.03 |